Yes, I'm still here!
For what it's worth, from my past experience at the interface of clinical medicine and BP, Don's record, his age, the fact that Dr Wong has left, and that Dr Johansson is also involved in another company, I cannot imagine a BP any BP pumping enough cash into RVX to support a long-term clinical program. They will be interested in the drug but not the team. They will want to do it themselves. So the only prospect I can see is an acquisition. Don may be wrangling over the price. But Hawaii is calling! Just my opinion.
